Daily Pharma Scoop 2017-09-21: Intercept’s buy opportunity, Alcobra’s Downfall, Shire’s Japanese Approval
- Intercept may present a buy opportunity for risk prone investors.
- Alcobra has cash, but is that worth betting on?
- Shire extends its market in Japan.
Avisol Capital Partners, managed by Drs Udaya Maiya and Ashok Dutta, is writing a daily scoop of all sorts of news, catalysts, ratings, and other actionable details for its watch list stocks (and the rest of the healthcare universe). The watch list is available to Total Pharma Tracker subscribers. Some sections, like the catalyst data, abstract selections, AdComm coverages, Buy/Sell summaries etc are also available to subscribers only. This is an abridged version; for the entire Pharma Scoop, please subscribe to our Marketplace service.
Our daily analysis of a stock with a major event/upside: Intercept’s Letter Overblown
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.